文献速递妇科生殖医学

多配体蛋白聚糖-1通过TGF-β信号调节部分子宫内膜异位症女性子宫内膜瘤的侵袭潜能

Syndecan-1 modulates the invasive potential of endometrioma via TGF-β signalling in a subgroup of women with endometriosis.
PubMed 文献 · Hum Reprod · 2020-01-01

研究利用15例子宫内膜异位症组织样本进行基因聚类,发现2例高表达SDC1、SDC4及TGF-β信号分子;这些样本的子宫内膜异位基质细胞形成的3D球体在TGF-β1处理后侵袭增强,而沉默SDC1可逆转该促侵袭表型。

要点

  • 子宫内膜异位症组织中存在基因表达异质性,2/15例高表达SDC1、SDC4和TGF-β信号分子。
  • 高表达亚组的CD90+CD73+CD105+基质细胞3D球体在TGF-β1处理后侵袭增强。
  • 沉默SDC1联合TGF-β1处理可逆转高表达亚组的促侵袭表型。

核心结论

  • 在部分卵巢子宫内膜异位症样本中观察到异常促侵袭表型,联合SDC1基因沉默与TGF-β1处理可逆转该表型。

研究设计与样本

  • 研究利用15例子宫内膜异位症组织(ASRM III-IV期)的预验证标志物面板进行基因聚类分亚组,并对CD90+CD73+CD105+子宫内膜异位基质细胞进行体外3D球体侵袭实验。

主要发现

  • 基因聚类显示2/15例样本(Endo-hi)高表达SDC1、SDC4及TGF-β信号分子(TGF-β1、ESR1、CTNNB1、SNAI1、BMI1),其余样本(Endo-lo)呈均一低表达。
  • Endo-hi的CD90+CD73+CD105+基质细胞3D球体在rhTGF-β1处理后SDC1表达异常且体外侵袭增强,Endo-lo无此表现。
  • Endo-hi的促侵袭反应在SDC1基因沉默联合TGF-β1处理后逆转。
  • SDC1沉默后经TGF-β1处理的3D球体转录组显示WNT和GPCR信号等癌症相关通路下调。

局限性

  • 估计约2.5%的子宫内膜异位症患者日后有发生卵巢癌的潜在风险。
  • 该队列中观察到的促癌分子改变可能与其日后卵巢癌的临床发生不相关,因此需要验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the physiological role of transforming growth factor-beta (TGF-β1) and syndecans (SDC1, SDC4) in endometriotic cells in women with endometriosis? SUMMARY ANSWER: We observed an abnormal, pro-invasive phenotype in a subgroup of samples with ovarian endometriosis, which was reversed by combining gene silencing of SDC1 with the TGF-β1 treatment. WHAT IS KNOWN ALREADY: Women with endometriosis express high levels of TGF-β1 and the proteoglycan co-receptors SDC1 and SDC4 within endometriotic cysts. However, how SDC1 and SDC4 expression is regulated by TGF-β1 and the physiological significance of the high expression in endometriotic cysts remains unknown as does the potential role in disease severity. STUDY DESIGN, SIZE, DURATION: We utilized a pre-validated panel of stem- and cancer cell-associated markers on endometriotic tissue (n = 15) to stratify subgroups of women with endometriosis. Furthermore, CD90+CD73+CD105+ (SC+) endometriotic stromal cells from these patient subgroups were explored for their invasive behaviour in vitro by transient gene inhibition of SDC1 or SDC4, both in the presence or absence of TGF-β1 treatment. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometriotic cyst biopsies (n = 15) were obtained from women diagnosed with ovarian endometriosis (ASRM Stage III-IV). Gene expression variability was assessed on tissue samples by applying gene clustering tools for the dataset generated from the pre-validated panel of markers. Three-dimensional (3D) spheroids from endometriotic SC+ were treated in vitro with increasing doses of TGF-β1 or the TGFBRI/II inhibitor Ly2109761 and assessed for SDC1, SDC4 expression and in vitro 3D-spheroid invasion. Transcriptomic signatures from the invaded 3D spheroids were evaluated upon combining transient gene silencing of SDC1 or SDC4, both in presence or absence of TGF-β1 treatment. Furthermore, nanoscale changes on the surface of endometriotic cells were analysed after treatment with TGF-β1 or TGFBRI/II inhibitor using atomic force microscopy. MAIN RESULTS AND THE ROLE OF CHANCE: Gene clustering analysis revealed that endometriotic tissues displayed variability in their gene expression patterns; a small subgroup of samples (2/15, Endo-hi) exhibited high levels of SDC1, SDC4 and molecules involved in TGF-β signalling (TGF-β1, ESR1, CTNNB1, SNAI1, BMI1). The remaining endometriotic samples (Endo-lo) showed a uniform, low gene expression profile. Three-dimensional spheroids derived from Endo-hi SC+ but not Endo-lo SC+ samples showed an aberrant expression of SDC1 and exhibited enhanced 3D-spheroid invasion in vitro, upon rhTGF-β1 treatment. However, this abnormal, pro-invasive response of Endo-hi SC+ was reversed upon gene silencing of SDC1 with the TGF-β1 treatment. Interestingly, transcriptomic signatures of 3D spheroids silenced for SDC1 and consecutively treated with TGF-β1, showed a down-regulation of cancer-associated pathways such as WNT and GPCR signalling. LARGE SCALE DATA: Transcriptomic data were deposited in NCBI's Gene Expression Omnibus (GEO) and could be retrieved using GEO series accession number: GSE135122. LIMITATIONS, REASONS FOR CAUTION: It is estimated that about 2.5% of endometriosis patients have a potential risk for developing ovarian cancer later in life. It is possible that the pro-oncogenic molecular changes observed in this cohort of endometriotic samples may not correlate with clinical occurrence of ovarian cancer later in life, thus a validation will be required. WIDER IMPLICATIONS OF THE FINDINGS: This study emphasizes the importance of interactions between syndecans and TGF-β1 in the pathophysiology of endometriosis. We believe that this knowledge could be important in order to better understand endometriosis-associated complications such as ovarian cancer or infertility. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Cancerfonden (CAN 2016/696), Radiumhemmets Forskningsfonder (Project no. 154143 and 184033), EU MSCA-RISE-2015 project MOMENDO (691058), Estonian Ministry of Education and Research (IUT34-16), Enterprise Estonia (EU48695) and Karolinska Institute. Authors do not have any conflict of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ponandai-Srinivasan S, Saare M, Boggavarapu NR, et al. Syndecan-1 modulates the invasive potential of endometrioma via TGF-β signalling in a subgroup of women with endometriosis. Hum Reprod. 2020. PMID: 32897364. doi:10.1093/humrep/deaa164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。